Health business investment deal numbers are down. Way down.
But the companies getting funded? They’re hitting it big.
This is 2025’s weirdest money story. And it’s creating opportunities most people are missing.
The Numbers Tell a Wild Story
Here’s what happened in the first half of 2025:
Financings dropped 13% from last year. Only 336 deals got done. That’s the lowest number in years.
M&A deals fell even harder. Only 86 transactions happened. If this pace continues, we’ll see 20% fewer deals than 2023.
Sounds terrible, right?
Wrong.
Why Less Is Actually More
Here’s the twist nobody saw coming. With fewer deals happening, the money is getting concentrated.
Think about it. Same amount of investor cash. Fewer companies to split it between. Each winner gets a bigger slice.
The companies that do get funded are raising serious money:
- Fay raised $25 million for nutrition counseling
- AtmosZero closed $21 million
- Crown Affair secured $9 million
- ModifyHealth got $13.5 million
These aren’t small checks. These are game-changing rounds.
The Pickiness Advantage
Investors got super picky in 2025. They stopped funding everything. Now they only fund the best stuff.
This created two groups:
- The chosen few: Getting tons of money and attention
- Everyone else: Getting nothing
If you’re in the chosen few, life is amazing. If you’re not, you’re struggling.
But here’s the secret. Being in the chosen few isn’t about luck. It’s about understanding what investors actually want right now.
What’s Actually Getting Funded
The data shows five clear trends for what’s hot:
1. GLP-1 and Ozempic Solutions Major players like Nestlé are repositioning entire brands around this. It’s bigger than weight loss. It’s a complete market shift.
2. Personalized Nutrition Fay’s $25 million round proves it. People want custom solutions, not generic products.
3. Food as Medicine ModifyHealth’s funding shows investors believe food can replace drugs for some conditions.
4. Technology-Enabled Health Apps, AI, and data are making health products smarter and more effective.
5. Sustainable Nutrition Climate-conscious health solutions are getting serious money.
The Technology Shift
Here’s a big change. Money is flowing from brands to technology.
Old way: Fund a supplement brand, hope it gets big. New way: Fund the technology that makes many brands possible.
Investors realized something. Brands are risky. Technology platforms serve many brands. That’s safer and more scalable.
This explains why AgTech/FoodTech/Biotech deals are actually up 7% while everything else is down.
The Ozempic Effect
Let’s talk about the elephant in the room. GLP-1 drugs like Ozempic changed everything.
Suddenly, 20 million Americans are on weight loss drugs. These people have new needs:
- They eat less but need more nutrients
- They have side effects that need solutions
- They want healthy, high-protein foods
This created a massive new market overnight. Smart companies are building products specifically for GLP-1 users.
Investors call this a “gamechanger.” And they’re throwing money at it.
Why Timing Matters Right Now
Most people think this investment drought is bad news. They’re wrong.
This is actually the perfect time to start a health company. Here’s why:
Less competition. Most entrepreneurs gave up. The field is wide open.
Desperate investors. They need good deals. If you have one, they’ll pay premium prices.
Proven concepts only. The market killed all the weak ideas. Only the strong ones survive.
Lower costs. Everything from talent to manufacturing is cheaper now.
The Secret Pattern
I noticed something interesting in the successful deals. They all follow the same pattern:
Step 1: Identify a specific health problem that affects millions of people.
Step 2: Create a technology-enabled solution (not just another supplement).
Step 3: Prove it works with real data and customers.
Step 4: Show how it can scale beyond just one product.
Companies that follow this pattern get funded. Companies that don’t, get ignored.
The Green Shoots Nobody Talks About
Despite all the doom and gloom, smart money sees opportunity everywhere.
March 2024 showed promise. Health and nutrition financings were up 5% from March 2023. Food and beverage transactions jumped 7%.
This suggests the worst is over. Money is starting to flow again. But it’s flowing differently.
The International Angle
Here’s something most people miss. While U.S. deals are down, international opportunities are exploding.
Europe is leading innovation in women’s supplements. Asia is driving personalized nutrition. Germany just had its largest AgTech Series A ever.
Smart investors are looking globally. They’re finding opportunities where others only see problems.
What This Means for Everyone
For Entrepreneurs: Don’t wait for the market to recover. Start now while competition is low.
For Investors: The best deals are happening right now. But you need to be very selective.
For Employees: Join health companies that got recent funding. They’re the ones with staying power.
For Consumers: Expect better, more targeted health products. The weak companies are gone.
The 2025 Prediction
Based on all the data, here’s what I think happens next:
The investment drought continues for most companies. But the winners get even bigger rounds.
Technology becomes more important than brands. Platforms beat products.
Ozempic and GLP-1 create an entirely new health category worth billions.
International expansion becomes the key to growth.
Personalization goes from nice-to-have to must-have.
The Opportunity Hidden in Plain Sight
While everyone focuses on the declining deal numbers, they’re missing the real story.
The companies that survive this drought will dominate the next decade. They’ll have less competition, more resources, and proven business models.
This isn’t a crisis. It’s a filtering process. And the filter is working.
The Bottom Line
2025’s investment story isn’t about fewer deals. It’s about better deals.
Quality is replacing quantity. Strategy is replacing hope. Technology is replacing hype.
The companies that understand this are raising huge rounds while their competitors disappear.
The investment drought isn’t making everyone poor. It’s making the smart players incredibly rich.
The question isn’t whether you can survive the drought. The question is whether you’re smart enough to use it to your advantage.
Because while everyone else is complaining about the lack of money, the winners are quietly collecting all of it.
Breakthrough The Supplement Revenue Ceiling
This diagnostic reveals the specific bottlenecks limiting your supplement brand’s revenue growth and provides a clear optimization pathway for breakthrough.
Listen to the Health Supplement Business Mastery Podcast for for dietary supplement entrepreneurs and marketers.
